U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06813911) titled 'Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD' on Feb. 03.
Brief Summary: The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated Lipoprotein A (Lp(a)), and who are on background inclisiran treatment for elevated Lipoprotein associated cholesterol (LDL-C).
Study Start Date: May 28, 2025
Study Type: INTERVENTIONAL
Condition:
Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention:
DRUG: Pelacarsen
Pelacarsen will be pr...